Universal Beteiligungs und Servicegesellschaft mbH Invests $1.35 Million in Billiontoone, Inc. $BLLN

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH opened a new Q4 position in BillionToOne (BLLN), buying 16,473 shares worth about $1.35M, while other institutions — notably Baillie Gifford and Massachusetts Financial Services — added much larger stakes (~$103.79M and ~$13.37M, respectively).
• BillionToOne beat quarterly expectations with $0.11 EPS versus $0.04 expected and $96.05M revenue (up 113% YoY); the stock trades near $77.49, has a $3.56B market cap and a P/E around 369.
• Analyst views are mixed but lean positive — six Buys, three Holds and one Sell — giving an average rating of "Moderate Buy" and an average target price of $126.71, even as several firms recently cut price targets.

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Billiontoone, Inc. (NASDAQ:BLLN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 16,473 shares of the company's stock, valued at approximately $1,348,000.

Several other large investors also recently added to or reduced their stakes in the stock. Baillie Gifford & Co. bought a new stake in Billiontoone during the fourth quarter worth approximately $103,786,000. Massachusetts Financial Services Co. MA bought a new stake in Billiontoone during the fourth quarter worth approximately $13,373,000. FNY Investment Advisers LLC bought a new stake in Billiontoone during the fourth quarter worth approximately $497,000. Finally, Green Alpha Advisors LLC bought a new stake in Billiontoone during the fourth quarter worth approximately $436,000.

Analyst Upgrades and Downgrades

BLLN has been the topic of several analyst reports. Weiss Ratings initiated coverage on Billiontoone in a research note on Tuesday, February 3rd. They set a "sell (d)" rating on the stock. Wells Fargo & Company reduced their price objective on Billiontoone from $110.00 to $90.00 and set an "equal weight" rating on the stock in a research note on Thursday, March 5th. Wall Street Zen raised Billiontoone from a "hold" rating to a "buy" rating in a research note on Saturday, March 7th. BTIG Research reduced their price objective on Billiontoone from $160.00 to $140.00 and set a "buy" rating on the stock in a research note on Thursday, March 5th. Finally, Guggenheim reduced their price objective on Billiontoone from $120.00 to $100.00 and set a "buy" rating on the stock in a research note on Monday, March 30th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $126.71.

Billiontoone Price Performance

Shares of NASDAQ:BLLN opened at $77.49 on Friday. Billiontoone, Inc. has a 1 year low of $61.96 and a 1 year high of $138.70. The company's 50 day simple moving average is $77.44. The stock has a market capitalization of $3.56 billion and a price-to-earnings ratio of 369.00. The company has a quick ratio of 11.32, a current ratio of 11.69 and a debt-to-equity ratio of 0.12.

Billiontoone (NASDAQ:BLLN - Get Free Report) last announced its earnings results on Wednesday, March 4th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.07. The business had revenue of $96.05 million for the quarter, compared to analysts' expectations of $85.85 million. The business's revenue was up 113.0% compared to the same quarter last year. Equities research analysts expect that Billiontoone, Inc. will post 0.42 EPS for the current fiscal year.

Billiontoone Profile

BillionToOne NASDAQ: BLLN is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

Want to see what other hedge funds are holding BLLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Billiontoone, Inc. (NASDAQ:BLLN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.